Abstract 5P
Background
We tested whether the longitudinal monitoring of peripheral blood (PB) immune-inflammatory benchmarks might intercept immune-related adverse events (irAEs) onset and their impact on clinical outcome in ICI-treated NSCLC.
Methods
On PB collected at baseline (T0) and first disease assessment (T1) from 105 advanced NSCLC undergoing ICIs, comprehensive immune cell phenotyping (flow-cytometry), LDH, derived Neutrophil-to-Lymphocyte ratio (dNLR), LIPI and serum multiplex cytokine array were prospectively evaluated, including their delta (Δ) variation [(T1-T0)/T0*100]. irAEs type and grading (G) were defined according to CTCAE (Common Terminology Criteria in Adverse Events) v5.0. Correlations of irAEs with clinicopathological/PB parameters and survival outcome were statistically analyzed.
Results
irAEs occurred in 51 (48.6%) patients with 14.3% G3-4 incidence and involving the skin (36%), diarrhea/colitis (24%), liver (12%), thyroid (4%) and multiple sites (33.3%); median time-to-onset: 48-278 days; and leading to temporary or permanent ICI discontinuation in 11.4% of cases. irAEs were more frequent in females (58.3%) and absent in performance status (PS) 2 patients. Baseline PB parameters didn’t substantially differ according to irAE occurrence, except for higher IFNγ (P=0.014) and lower IL1β and IL6 (P=0.02) levels in irAEs cases. At T1, lower NLR, dNLR and LIPI characterized irAE patients, together with increased CD8+ cytotoxic (Perforin+, P=0.09) and proliferating (Ki67+, P=0.05) activity, higher IFNγ and TNFα and lower TGFβ1 levels compared to no-irAEs cases. Intriguingly, PB immune cells dynamic more closely reflected irAE severity as G3-4 cases displayed a sharp rise (Δpos) in cytotoxic NKs and CD8+GnzB+ lymphocytes (P=0.04) and a drop (Δneg) in CD4+CD25+FOX3high Tregs (P=0.07). Importantly, irAEs patients exhibited greater disease control rate (84% vs 65.1%, P=0.05) and significantly longer PFS (Median PFS=10.4 vs 5.4 mos, P=0.002, HR=0.47) and OS (Median OS=NR vs 11.3 mos, P<0.001, HR=0.34) vs no-irAEs NSCLC.
Conclusions
irAEs involve a distinctive cellular and humoral immune dynamic and might positively condition ICI efficacy.
Legal entity responsible for the study
University Hospital of Parma.
Funding
Associazione Italiana per la Ricerca sul Cancro-AIRC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display